CLAIMS

1. A pharmaceutical composition, which comprises 1.0-3.0 mg/ml of edaravone, 0.2-1.0 mg/ml of dextrocamphol, 0.95-1.05 mg/ml of sodium metabisulphite, propylene glycol, and water for injection, wherein, the active ingredients of the pharmaceutical composition are edaravone and dextrocamphol ; and the structural formula of dextrocamphol is as follows:



2. The pharmaceutical composition according to claim 1, characterised in that the weight ratio of edaravone to dextrocamphol is 1 : 1-4 : 1;

preferably, the weight ratio of edaravone to dextrocamphol is 4 : 1;

preferably, the weight ratio of edaravone, dextrocamphol and sodium metabisulphite in the pharmaceutical composition is 4 : 1 : 2.

3. The pharmaceutical composition according to claim 1 or 2, wherein, the content of edaravone is 2.0 mg/ml;

and/or the content of dextrocamphol in the pharmaceutical composition is 0.5 mg/ml;

and/or the content of sodium metabisulphite is 0.97-1.03 mg/ml, preferably, the content of sodium metabisulphite is 1.0 mg/ml.

4. The pharmaceutical composition according to any one of claims 1-3, characterised in that the pharmaceutical composition further contains a compound of formula I or a pharmaceutically acceptable salt thereof,



Formula I;

preferably, the weight ratio of the compound of formula I or a pharmaceutically acceptable salt thereof to edaravone is 0.3% or less.

5. The pharmaceutical composition according to any one of claims 1-4, characterised in that the pharmaceutical composition further contains a compound of formula II or a pharmaceutically acceptable salt thereof,



Formula II;

preferably, the weight ratio of the compound of formula II or a pharmaceutically acceptable salt thereof to edaravone is 0.3% or less.

6. The pharmaceutical composition according to claim 5, characterised in that the pharmaceutical composition comprises the compound of formula I or a pharmaceutically acceptable salt thereof in a weight ratio to edaravone of 0.3% or less, and the compound of formula II or a pharmaceutically acceptable salt thereof in a weight ratio to edaravone of 0.3% or less.

7. Use of the pharmaceutical composition according to any one of claims 1-6 in the preparation of a pharmaceutical preparation for treating cerebral stroke, amyotrophic lateral sclerosis or related disorders.